In March 2024, a scoping review of 15 clinical trials, six case reports and one retrospective cohort study, published in the Journal of the American Academy of Dermatology reported that dysaesthesia occurred in 6 of 334 participants (1.8%) taking semaglutide and not in any patients taking placebo
Despite these limitations, this study validates the safety of combined cagrilintide and semaglutide pharmacotherapy, justifying additional studies to evaluate efficacy for weight management in obesity
Davies et al., JAMA 2021) reported psychiatric adverse events at similar rates between semaglutide and placebo groups, suggesting no clear direct causation
When you visit us, we will: Your weight loss goals and timeline Medical history and current medications Insurance coverage and financial considerations Previous weight loss attempts and responses Cardiovascular risk factors Personal preferences and lifestyle factors Our comprehensive approach combines these medications with our expertise in bariatric surgery when appropriate, offering you the full spectrum of weight loss solutions
This multifaceted approach leads to significant weight loss and improved glycemic control
